Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vir Biotechnology Inc's Business Segments
Vir Biotechnology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 3 | 100% |
Revenue by Product & Service Category - Q1 FY2025
- Other Revenue61.5%
- Grant40.8%
- License and Collaboration Revenue0%
Revenue by Product & Service Category - Q1 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Other Revenue | $ 2 | 61.5% |
| Grant | $ 1 | 40.8% |
| License and Collaboration Revenue | $ 0 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vir Biotechnology Inc
Vir Biotechnology Inc is a clinical-stage immunology company focused on developing therapies to treat infectious diseases.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.
Vir Biotechnology Inc. is a prominent clinical-stage immunology company dedicated to the development of innovative therapeutic solutions targeted at infectious diseases across the globe. The company leverages its advanced platform technologies and extensive pipeline of product candidates to address critical unmet medical needs. Below is a comprehensive overview of the key segments, products, and services offered by Vir Biotechnology.
Segments
1. Infectious Diseases:
This segment of Vir Biotechnology comprises a variety of products designed to combat infectious diseases, with a particular emphasis on the ongoing fight against severe viral infections. Key focus areas include:
- VIR-7831: A fully human monoclonal antibody intended for the treatment of COVID-19. Its design aims to induce a robust immune response, enabling it to neutralize the SARS-CoV-2 virus effectively. Clinical trials have shown significant promise, and it is in Phase III studies as a treatment for COVID-19.
- VIR-2482: This candidate is pivotal in the companys commitment to developing a universal flu vaccine that aims to provide long-term immunity against multiple strains of the influenza virus. Currently positioned in Phase II clinical trials, it represents a major step toward more effective flu prevention.
- VIR-1111: This investigational monoclonal antibody is aimed at preventing and treating chronic Hepatitis B virus (HBV) infections. VIR-1111 is undergoing Phase I clinical trials, demonstrating Virs dedication to tackling persistent viral infections that pose significant health challenges worldwide.
2. Immunology:
This segment focuses on harnessing the potential of the immune system to treat autoimmune diseases. Products under this category encompass:
- Investigational Candidates for Autoimmune Diseases: Vir Biotechnology is developing several product candidates aimed at conditions like rheumatoid arthritis, inflammatory bowel disease (IBD), and multiple sclerosis (MS), catering to a wide scope of immune-mediated conditions.
Products and Services
Vir Biotechnology’s robust portfolio includes several advanced products and services that are designed to offer innovative solutions to various infectious diseases and immune disorders:
1. VIR-7831: In-depth clinical studies for this monoclonal antibody have reported significant neutralizing activity against SARS-CoV-2. Its mechanism of action revolves around the binding affinity to the spike protein of the virus, thereby preventing its entry into human cells. The ongoing clinical trials are expected to provide critical data on its efficacy and further therapeutic uses.
2. VIR-2482: Focused on providing broad, long-lasting protection against influenza, this universal vaccine aims to overcome some limitations of current seasonal flu vaccines, which often must be updated annually. With Phase II trials nearing completion, insights into its performance against various influenza strains are highly anticipated.
3. VIR-1111: This antibody shows promise not just in virus clearance, but in potentially re-establishing a functional immune response against chronic HBV. As it progresses through clinical trials, data will shed light on its role in managing viral load and liver health in HBV-infected patients.
4. mRNA Platform Technology: Virs proprietary mRNA platform technology utilizes messenger RNA to instruct cells to produce specific proteins that elicit an immune response. This method capitalizes on the bodys natural immune mechanisms to develop vaccines aimed at a variety of infectious diseases, showcasing Virs commitment to innovation.
5. Antiviral Platform Technology: The antiviral platform is designed to hinder the replication of viruses, providing a versatile tool in the creation of antiviral therapies. By targeting various viral mechanisms, this technology holds the potential for broad-spectrum antiviral interventions.
6. Immune Modulating Platform Technology: This platform is dedicated to reprogramming and activating immune cells, which could be transformative in treating diseases like cancer and various autoimmune disorders. The ability to manipulate the immune response is central to developing novel therapeutic strategies and enhancing patient outcomes.
Partnerships and Collaborations
Vir Biotechnology has formed strategic partnerships with leading pharmaceutical companies, academic institutions, and government entities. Collaborative efforts with organizations such as GlaxoSmithKline and Alnylam Pharmaceuticals focus on accelerating the development of their product candidates. Additionally, partnerships with federal health agencies like the National Institute of Allergy and Infectious Diseases (NIAID) enhance research capabilities, expanding the reach of Virs innovative solutions in the fight against infectious diseases.
Conclusion
Vir Biotechnology Inc. combines a robust portfolio of advanced therapeutic candidates, innovative platform technologies, and strategic collaborations to develop impactful solutions in immunology and infectious disease treatment. Its commitment to addressing significant global health issues positions it as a key player in the biopharmaceutical sector, with ongoing research and development aimed at making a meaningful difference in patient care worldwide.
Segments
1. Infectious Diseases:
This segment of Vir Biotechnology comprises a variety of products designed to combat infectious diseases, with a particular emphasis on the ongoing fight against severe viral infections. Key focus areas include:
- VIR-7831: A fully human monoclonal antibody intended for the treatment of COVID-19. Its design aims to induce a robust immune response, enabling it to neutralize the SARS-CoV-2 virus effectively. Clinical trials have shown significant promise, and it is in Phase III studies as a treatment for COVID-19.
- VIR-2482: This candidate is pivotal in the companys commitment to developing a universal flu vaccine that aims to provide long-term immunity against multiple strains of the influenza virus. Currently positioned in Phase II clinical trials, it represents a major step toward more effective flu prevention.
- VIR-1111: This investigational monoclonal antibody is aimed at preventing and treating chronic Hepatitis B virus (HBV) infections. VIR-1111 is undergoing Phase I clinical trials, demonstrating Virs dedication to tackling persistent viral infections that pose significant health challenges worldwide.
2. Immunology:
This segment focuses on harnessing the potential of the immune system to treat autoimmune diseases. Products under this category encompass:
- Investigational Candidates for Autoimmune Diseases: Vir Biotechnology is developing several product candidates aimed at conditions like rheumatoid arthritis, inflammatory bowel disease (IBD), and multiple sclerosis (MS), catering to a wide scope of immune-mediated conditions.
Products and Services
Vir Biotechnology’s robust portfolio includes several advanced products and services that are designed to offer innovative solutions to various infectious diseases and immune disorders:
1. VIR-7831: In-depth clinical studies for this monoclonal antibody have reported significant neutralizing activity against SARS-CoV-2. Its mechanism of action revolves around the binding affinity to the spike protein of the virus, thereby preventing its entry into human cells. The ongoing clinical trials are expected to provide critical data on its efficacy and further therapeutic uses.
2. VIR-2482: Focused on providing broad, long-lasting protection against influenza, this universal vaccine aims to overcome some limitations of current seasonal flu vaccines, which often must be updated annually. With Phase II trials nearing completion, insights into its performance against various influenza strains are highly anticipated.
3. VIR-1111: This antibody shows promise not just in virus clearance, but in potentially re-establishing a functional immune response against chronic HBV. As it progresses through clinical trials, data will shed light on its role in managing viral load and liver health in HBV-infected patients.
4. mRNA Platform Technology: Virs proprietary mRNA platform technology utilizes messenger RNA to instruct cells to produce specific proteins that elicit an immune response. This method capitalizes on the bodys natural immune mechanisms to develop vaccines aimed at a variety of infectious diseases, showcasing Virs commitment to innovation.
5. Antiviral Platform Technology: The antiviral platform is designed to hinder the replication of viruses, providing a versatile tool in the creation of antiviral therapies. By targeting various viral mechanisms, this technology holds the potential for broad-spectrum antiviral interventions.
6. Immune Modulating Platform Technology: This platform is dedicated to reprogramming and activating immune cells, which could be transformative in treating diseases like cancer and various autoimmune disorders. The ability to manipulate the immune response is central to developing novel therapeutic strategies and enhancing patient outcomes.
Partnerships and Collaborations
Vir Biotechnology has formed strategic partnerships with leading pharmaceutical companies, academic institutions, and government entities. Collaborative efforts with organizations such as GlaxoSmithKline and Alnylam Pharmaceuticals focus on accelerating the development of their product candidates. Additionally, partnerships with federal health agencies like the National Institute of Allergy and Infectious Diseases (NIAID) enhance research capabilities, expanding the reach of Virs innovative solutions in the fight against infectious diseases.
Conclusion
Vir Biotechnology Inc. combines a robust portfolio of advanced therapeutic candidates, innovative platform technologies, and strategic collaborations to develop impactful solutions in immunology and infectious disease treatment. Its commitment to addressing significant global health issues positions it as a key player in the biopharmaceutical sector, with ongoing research and development aimed at making a meaningful difference in patient care worldwide.